Additionally, PAK1 inhibition is plausible for cancers in which PAK1 converges crucial signaling transductions of aberrated oncogenes (e.g, ErbB2, TRIO) or tumor suppressor genes (e,g NF1) 13, 34, 35. The gene discussed is PAK1; the disease is cancer.